COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Abstract Background Monoclonal antibody (mAb) treatment for COVID-19 is associated with improved clinical outcomes. However, there is limited information regarding the impact of treatment on symptoms and the prevalence of post-COVID Conditions (PCC). Understanding of the association between time to...

Full description

Bibliographic Details
Main Authors: Natalie L. Vawter, Job G. Godino, Sydney V. Lewis, Adam W. Northrup, Jane C. Samaniego, Jacqueline Y. Poblete, Jesus A. Guereca, Sydney P. Sharp, Eva Matthews, Noe C. Crespo, Pauline G. Lucatero, Monica M. Vidaurrazaga, Christian B. Ramers
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
Monoclonal antibodies
COVID-19 symptoms
Post-COVID conditions
Online Access:https://doi.org/10.1186/s12879-023-08057-7

Internet

https://doi.org/10.1186/s12879-023-08057-7

Similar Items